Alzheimer's drug developer Probiodrug, the backers of which include Biogen Idec, has set the range for a proposed initial public offering in the Netherlands.
Germany-based biopharmaceutical company Probiodrug, which is backed by pharmaceutical corporation Biogen Idec, has priced its initial public offering.
The company plans to raise up to €32m ($40.8m), and will offer up to 1.7 million shares on the Euronext Amsterdam market priced between €15.25 and €19.00 per share.
Probiodrug is researching and developing novel therapeutic solutions to treat people with Alzheimer’s disease. Funds raised through the offering will be used to further develop drug candidates, and to broaden research.
Probiodrug has…
